Kenneth Moch small.jpg

Kenneth I. Moch, Managing Partner, has broad expertise building, managing and financing private and public life science companies from start-up through commercialization, and has helped build five companies which have pioneered novel technologies. Ken has served as President & CEO of four life science companies: Chimerix, Inc. (NASDAQ:CMRX), a public antiviral therapeutics company which is developing brincidofovir as the first broad spectrum agent against DNA viruses; BioMedical Enterprises, a manufacturer and marketer of nitinol orthopedic implants; Alteon, Inc., a developer of small molecule therapeutics for cardiovascular aging and diabetic complications; and Biocyte Corporation, where he pioneered the storage and therapeutic use of cord blood stem cells and launched the first cord blood stem cell storage bank. He was also a co-founder and Vice President of The Liposome Company, Inc., a pioneer in the use of liposomes for the delivery of anticancer and antifungal drugs. During the course of his career Ken has also been a Managing Director of Healthcare Investment Banking at ThinkEquity Partners and a management consultant with McKinsey & Company. Building on his longstanding interest in health policy, Ken served for over a decade on the Board of the Biotechnology Industry Organization (BIO), as Secretary of BIO’s Emerging Companies Section, and as a member of the BIO’s BioEthics Committee. He is a member of the Board of North Carolina Bio (NCBio), and is a past Chairman of Bio New Jersey (BioNJ) and a past member of the Executive Committee of the New York Biotechnology Association. Ken is a member of the NYU Working Group on Compassionate Use and Pre-Approval Access and recently joined the National Advisory Board of the Johns Hopkins Berman Institute of Bioethics. In August 2014, Ken and Arthur Caplan, the Head of Medical Ethics at NYU Medical Center, co-authored an article in Health Affairs on the ethical issues surrounding access to experimental medicines, "Rescue Me: The Challenge Of Compassionate Use In The Social Media Era." In March 2015 Ken contributed an Op-Ed to The Wall Street Journal entitled, “Wanted: Guidelines for Access to Experimental Drugs.” Ken currently serves on the Board of Zynerba, Inc., and as a member of the Board of M2Gen - Moffitt Genetics Corporation, the personalized medicine subsidiary of Moffitt Cancer Center. He holds an A.B. in biochemistry from Princeton University and an MBA from the Stanford University Graduate School of Business.